Publication Digest: A minimum dataset for destination therapy with left ventricular assist device: the evidence that matters to decision makers

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-Based Publications Digest. In a recent publication, Chu et al. conducted a systematic review to develop an admission criterion framework for high-cost medical consumables in governmental hospitals. The study was carried out in a multi-country context and established a framework with seven first-level and 23 second-level indicators, highlighting the primacy of “Clinical Benefit,” followed by “Economic Value,” and “Organizational Impact.” This framework helps decision-makers ensure both efficient resource allocation and robust clinical outcomes.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Cimprich et al. discussed strategies of regulatory actors, particularly market authorization agencies, health technology assessment agencies, and health care procurement agencies, for integrating environmental sustainability requirements into the regulation of medicines and medical devices. Their analysis, contextualized within diverse healthcare settings, reveals significant untapped possibilities for strengthening regulatory frameworks to mitigate the ecological footprint of health technologies.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, van den Broek-Altenburg et al. reviewed 20–25 years of economic value assessment approaches in healthcare, highlighting the growing focus on individual preferences over broad societal metrics in value-based care models. The study underscores the complexities of incorporating patient-specific preferences into economic evaluations, and addresses recognized limitations of QALY measures. The authors discussed emerging alternative valuation frameworks that could influence future policy and reimbursement decision-making.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Schweitzer et al. explored the suitability of the current German HTA dossier templates for the impending EU joint clinical assessment (JCA). The study examined how extensively safety endpoint and subgroup analyses in German dossiers were actually considered by IQWiG and the G-BA. The authors found that the current German HTA templates significantly increased the workload of HTA developers while leaving many reported outcomes unconsidered by IQWiG and G-BA. To mitigate duplicative efforts and ensure prompt availability of medicinal products in line with the EU HTA Regulation framework, the authors recommend well-defined dossier requirements, early consultations, and proactive engagement with HTA developers.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-based Publications Digest. In a recent publication, Otte et al. synthesized expert discussions on the challenges and opportunities of implementing Value-Based Healthcare and Health Technology Assessment in emerging markets.The study highlighted the importance of Real-World Evidence in biosimilar value assessment and decision-making processes. The authors proposed Multi-Criteria Decision Analysis as a tool for optimizing pharmaceutical procurement in resource-constrained settings. The findings emphasized the need for stronger interdisciplinary collaboration among stakeholders and the expansion of public-private partnerships to address healthcare access barriers and drive system-wide improvements.